These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 28393712)
41. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Gillard M; Fuks B; Leclercq K; Matagne A Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627 [TBL] [Abstract][Full Text] [Related]
42. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. Madeo M; Kovács AD; Pearce DA J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386 [TBL] [Abstract][Full Text] [Related]
43. Imaging of Synaptic Density in Neurodegenerative Disorders. Carson RE; Naganawa M; Toyonaga T; Koohsari S; Yang Y; Chen MK; Matuskey D; Finnema SJ J Nucl Med; 2022 Jun; 63(Suppl 1):60S-67S. PubMed ID: 35649655 [TBL] [Abstract][Full Text] [Related]
44. Synaptic vesicle protein 2A: basic facts and role in synaptic function. Mendoza-Torreblanca JG; Vanoye-Carlo A; Phillips-Farfán BV; Carmona-Aparicio L; Gómez-Lira G Eur J Neurosci; 2013 Dec; 38(11):3529-39. PubMed ID: 24102679 [TBL] [Abstract][Full Text] [Related]
45. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A. Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505 [TBL] [Abstract][Full Text] [Related]
47. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992 [TBL] [Abstract][Full Text] [Related]
48. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204 [TBL] [Abstract][Full Text] [Related]
49. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation. Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049 [TBL] [Abstract][Full Text] [Related]
50. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam. Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968 [TBL] [Abstract][Full Text] [Related]
51. Synaptic vesicle protein 2A mitigates parthanatos via apoptosis-inducing factor in a rat model of pharmacoresistant epilepsy. Li C; Wang Z; Ren M; Ren S; Wu G; Wang L CNS Neurosci Ther; 2024 May; 30(5):e14778. PubMed ID: 38801174 [TBL] [Abstract][Full Text] [Related]
52. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants. Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444 [TBL] [Abstract][Full Text] [Related]
53. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214 [TBL] [Abstract][Full Text] [Related]
55. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem. Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262 [TBL] [Abstract][Full Text] [Related]
56. PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. Cai Z; Li S; Matuskey D; Nabulsi N; Huang Y Neurosci Lett; 2019 Jan; 691():44-50. PubMed ID: 30075287 [TBL] [Abstract][Full Text] [Related]
57. Synthesis and Preclinical Evaluation of an Cai Z; Li S; Zhang W; Pracitto R; Wu X; Baum E; Finnema SJ; Holden D; Toyonaga T; Lin SF; Lindemann M; Shirali A; Labaree DC; Ropchan J; Nabulsi N; Carson RE; Huang Y ACS Chem Neurosci; 2020 Feb; 11(4):592-603. PubMed ID: 31961649 [TBL] [Abstract][Full Text] [Related]
58. Imaging synaptic density in the living human brain. Finnema SJ; Nabulsi NB; Eid T; Detyniecki K; Lin SF; Chen MK; Dhaher R; Matuskey D; Baum E; Holden D; Spencer DD; Mercier J; Hannestad J; Huang Y; Carson RE Sci Transl Med; 2016 Jul; 8(348):348ra96. PubMed ID: 27440727 [TBL] [Abstract][Full Text] [Related]
59. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. Wu PP; Cao BR; Tian FY; Gao ZB Neurosci Bull; 2024 May; 40(5):594-608. PubMed ID: 37897555 [TBL] [Abstract][Full Text] [Related]